This is the authors' abstract. We don't add key points for this paper.
Since its discovery in 1982, Helicobacter pylori has quickly and irreversibly established itself as an important pathogen. Treatment of H pylori infection has revolutionized the management of peptic ulcer disease. There also is much interest about the role of H pylori in gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALToma). The link with cancer has led to new research, especially in the basic sciences. There are several H pylori gastric cancer models available that allow for research on the pathogenesis of cancer formation of this chronic infection. On the clinical side, much of the 1990s were spent on the development of efficacious treatments against H pylori infection. The current firstand second-line therapies were largely developed by trial and error in which different combinations of antibiotics were used with either proton pump inhibitors or bismuth-containing compounds. Regimens were refined using the results of numerous smaller and larger studies that evaluated different combinations of drugs. It is fair to say that little is known about the behaviour of antibiotics in the stomach. In fact, for most compounds, the mechanisms by which they exert their anti-H pylori activity are completely unknown. For example, it is not known whether some or all antibiotics kill the helicobacter organism topically as they pass through the stomach or whether first absorption in the proximal small bowel is necessary, with subsequent transfer of the active agent through the systemic circulation to the gastric mucosa. It seems likely that high mucosal concentrations of antibiotics are necessary to reach the helicobacter organisms that live deep in the gastric pits in the gastric mucous layer. It has become clear that acid suppression markedly improves the efficacy of antibiotics, especially the combination of clarithromycin and amoxicillin, but also clarithromycin and metronidazole. Furthermore, although the bismuth compounds are unable to kill and eradicate all H pylori organisms by themselves, they definitely enhance the antiH pylori activity when given concomitantly with other antibiotics such as tetracycline, metronidazole and amoxicillin. Further improvements in success rates can be achieved by combining bismuth compounds with a proton pump inhibitor and two antibiotics. Soon after treatment trials were launched, it became clear that H pylori can develop resistance to antibiotics. For example, H pylori is almost universally resistant to the quinolones, which is why these agents are not currently used in the treament of H pylori infection. Resistance to metronidazole also occurs frequently; resistance to clarithromycin occurs to a lesser extent. Until recently, resistance to amoxicillin and tetracycline was only rarely reported. A point mutation is responsible for clarithromycin resistance. Much progress has also been made in unravelling the mechanisms of metronidazole resistance; this situation is more complicated. Although the rdx gene was found to play an important role, it does not completely explain the mechanisms by which metronidazole resistance can develop. A clinical problem in the evaluation of resistance of H pylori to antibiotics is that methods by which this can be determined have not been standardized and may vary. This is especially true for resistance to metronidazole and far less for resistance to clarithromycin. The recently published guidelines by the National Committee for Clinical Laboratory
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sander Veldhuyzen van Zanten (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: